PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Final NICE green light for Janssen’s Stelara in UC

The National Institute for Health and Care Excellence (NICE) has now issued a final green light for NHS use of Janssen’s Stelara (ustekinumab) to treat ulcerative colitis.

The decision permits NHS doctors to prescribe the drug to treat moderately to severely active ulcerative colitis (UC) in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if: a tumour necrosis factor (TNF)-alpha inhibitor has failed, cannot be tolerated, or is unsuitable.

TNF-alpha inhibitors are the most commonly used biological treatment option in this setting, and people unable to take them are then usually offered vedolizumab. Both Stelara and vedolizumab have similar safety profiles and work differently to TNF-alpha inhibitors.

According to NICE, clinical trial evidence shows that Stelara is more effective than placebo for treating moderately to severely active ulcerative colitis. During the first eight weeks of treatment (induction), indirect comparisons suggest that Stelara might be more effective than one of the TNF-alpha inhibitors, but for maintenance treatment indirect comparisons suggest there is no difference between the treatments.

The Institute’s cost-effectiveness estimates for Stelara compared with vedolizumab are below what NICE considers a cost-effective use of NHS resources, and so it was able to recommend Janssen’s drug for when a TNF-alpha inhibitor is not appropriate or has not been effective.

However, its endorsement is contingent upon Janssen providing Stelara at the same price or lower than that agreed with the Commercials Medicines Unit.

Stelara is the first biologic therapy for UC that targets interleukin (IL)-12 and IL-23 cytokines, known to play a key role in inflammatory and immune responses, offering a new mechanism of action for treating the condition.

The drug is already recommended by NICE as a clinical and cost-effective option for the treatment of plaque psoriasis, psoriatic arthritis and Crohn’s disease.

Around 146,000 people in the UK have UC. It is a chronic immune-mediated inflammatory disease affecting the rectum and large intestine, for which there is currently no cure.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026